Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up Meeting Abstract
| Authors: | Gupta, S.; Rosenberg, J. E.; McKay, R. R.; Flaig, T. W.; Petrylak, D. P.; Hoimes, C. J.; Friedlander, T. W.; Bilen, M. A.; Srinivas, S.; Burgess, E. F.; Merchan, J. R.; Tagawa, S. T.; Brown, J. R.; Yu, Y.; Carret, A. S.; Wirtz, H.; Guseva, M.; Homet Moreno, B.; Milowsky, M. I. |
| Abstract Title: | Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4505 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4505 -- This meeting was also held virtually -- Source: Cinahl |
